Mitral stenosis (MS) of rheumatic aetiology is still a common valve disease in developing countries [1, 2] . It is characterised by a limitation to left atrial emptying which causes a progressive increase in mean left atrial pressure and pulmonary vascular bed pressures with development of pulmonary hypertension (PAH) and increased right ventricular (RV) pressure which influences the clinical manifestations and prognosis of the disease.
Introduction
Mitral stenosis (MS) of rheumatic aetiology is still a common valve disease in developing countries [1, 2] . It is characterised by a limitation to left atrial emptying which causes a progressive increase in mean left atrial pressure and pulmonary vascular bed pressures with development of pulmonary hypertension (PAH) and increased right ventricular (RV) pressure which influences the clinical manifestations and prognosis of the disease. 
Background
Percutaneous balloon mitral valvuloplasty (PMV) is an attractive therapeutic approach in patients with mitral stenosis. The aim of this study was to assess the immediate and long-term clinical, echocardiographic and haemodynamic outcomes of PMV in patients with severe pulmonary hypertension (PAH).
Increased pulmonary arterial pressure is often disproportional to left atrial pressure and is the result of significant increase in pulmonary vascular resistance [3] [4] [5] .
Surgical decompression of the left atrium, either through mitral commissurotomy or valve replacement generally produces a marked reduction in pulmonary artery pressure [6, 7] . However, as surgical mortality in this group of patients is high, percutaneous balloon mitral valvuloplasty (PMV) has emerged as a particularly attractive therapeutic approach in this population [8] [9] [10] [11] [12] . Up to the present time, there are a few publications on the long-term clinical outcome and pulmonary artery pressure response after PMV.
The aim of the study was to evaluate the immediate and long-term clinical outcomes and the changes in echocardiographic and haemodynamic parameters of patients with MS with and without PAH undergoing PMV.
Material and Methods
From January 1991 to December 2013, 157 patients with moderate to severe MS who underwent PMV were retrospectively enrolled. Patients were included if they met the following criteria: a) New York Heart Association (NYHA) functional class II or greater, in spite of optimal medical treatment; b) favourable anatomy by echocardiography (those patients with an unfavourable echocardiographic score were considered candidates for PMV according to their personal risk/ benefit ratio); c) absence of contraindications for transseptal catheterisation; d) lack of grade ! II mitral regurgitation according to Sellers classification [13] , and absence of concomitant valve disease requiring surgical treatment.
All patients gave their written informed consent to undergo the procedure and the study protocol. The study was conducted following the recommendations of the Declaration of Helsinki and was approved by the Committee on Ethics of our institution.
All the patients underwent transthoracic echocardiography before PMV, to evaluate mitral valve anatomy according to the Wilkins scoring system [14] . The mitral valve area (MVA) was determined by the pressure half-time method described by Hatle et al. [15] In patients with atrial fibrillation five cycles were averaged. After measuring the maximal velocity of the tricuspid regurgitation jet, pulmonary artery systolic pressure (PASP) was estimated using Bernoulli's equation in which right ventricular-right atrial gradient is added to mean right atrial pressure [16, 17] .
Transoesophageal echocardiography was performed within 72 hours before PMV to exclude left atrial thrombi.
Percutaneous balloon mitral valvuloplasty was performed using the INOUE device [18] (Toray Industries, Inc., Tokyo, Japan) in 153 patients and with the double balloon Multitrack device (NuMed, Inc., Hopkinton, NY, USA) in 4.
Right heart catheterisation was performed with balloon flow directed Swan-Ganz catheter and the following parameters were determined before and after the procedure: PASP, mean pulmonary artery pressure (PAMP), pulmonary artery diastolic pressure (PADP), pulmonary capillary wedge pressure (PCWP), right atrial pressure, RV pressure, cardiac output, trans-pulmonary pressure gradient (TPG, defined as the difference between PAMP and PCWP) and diastolic pulmonary vascular pressure gradient (DPG, defined as the difference between PADP and PCWP). Oxygen content was analysed from blood samples.
Patients were divided in two groups according to the PAMP measured by right heart catheterisation immediately before PMV: Group 1, patients with severe pulmonary artery hypertension (PAH), defined as PAMP ! 30 mm Hg, and Group 2: patients with PAMP 30 mmHg.
After PMV, left ventriculography was carried out to determine the presence and degree of mitral regurgitation.
Mitral valve area was assessed by Doppler echocardiography using the Gorlin method in the catheter laboratory immediately after the procedure, 72 hours later and during follow-up. Restenosis (Rs) was defined as loss of >50% of the initial gain of MVA by the preceding PMV with a final MVA <1.5 cm 2 [19, 20] .
Clinical and echocardiographic follow-up was performed during hospitalisation, at 1, 6 and 12 months and annually thereafter. Median follow-up was 48 months (24-84 months). Pulmonary artery pressure values were obtained only by echocardiography to avoid repeating catheterisations, as there was a very close correlation between the values obtained by this method and the baseline right heart catheterisation.
The primary end-points of the study were: 1) procedure success, defined as achievement of MVA !1.5 cm 2 without major complications (mortality, mitral regurgitation >II according to Sellers classification, systemic embolism or cardiac tamponade); 2) in-hospital mortality; 3) clinical improvement defined as !1-point New York Heart Association functional class improvement; 4) cardiovascular mortality. Secondary end-points were: 1) development or worsening of mitral valve regurgitation after the procedure or during follow-up; 2) procedure-related complications as needed for mitral valve replacement (MVR); 3) need for new PMV or deterioration to functional class to III or IV; and, 4) restenosis.
Statistical Analysis
Categorical variables are expressed as frequencies and percentages and were analysed by the chi square test or Fisher exact test. Continuous variables are expressed as mean AE standard deviation (SD) or median and interquartile range (IQR 25-75) and comparison of parametric and no parametric values between the two groups was performed by means of two-tailed Student t-test or Kruskal-Wallis test, as appropriate. The association between demographic, clinical and haemodynamic variables with PMV success and with the presence of PAH was evaluated. The cumulative survival curves were constructed with the Kaplan-Meier method and the Cox method was used to compare time-dependent covariates. All the calculations were performed using the Statistix1 7.0 software package and a p value < 0.05 was considered statistically significant.
Results
The cohort was made up of 157 patients with MS considered candidates for PMV. Mean age was 44.2 AE 13.3 years and 139 patients (88.5%) were women. Ninety-eight patients (62.4%) were in NYHA class II, 53 patients (33.7%) in class III and 6 patients (3.8%) in class IV. Atrial fibrillation was present in 31.8% of the patients; 10 patients (6.4%) had a history of mitral commissurotomy. The clinical, echocardiographic and haemodynamic characteristics of patients are summarised in Table 1 (Figure 1 ). No significant differences were observed between both groups in the outcome of MVA and PASP. No differences were observed in PHT progression in all patients with regard to Figure 3 ). There was no association between the presence of PAH and the outcome of MVA or survival free of restenosis at follow-up (group 1: 0,87 vs. group 2: 0,76; p=0,21). After four years of follow-up 109 patients remained asymptomatic (86.5%), 8 patients (6.3%) were on NYHA class II or III and 4 patients (3.1%) had palpitations. The number of asymptomatic patients was similar in both groups (Figure 4 ).
Discussion
In this study, we found that a high proportion of patients with severe MS have associated PAH. This prevalence was similar to those observed in other studies analysing the outcome of patients with PAH after PMV or surgical replacement [21] [22] [23] . Although most reports do not describe the percentage of patients with PAH, some registries with a larger number of patients showed mean or median PASP values similar to those of this study [19, 24, 25] .
The success rate in the total population was 79.6%, a result that fits within the reported range (73 to 99%) [19] [20] [21] 26 ].
An inverse relation has been described between the echocardiographic Wilkins score and outcome. The best immediate results were obtained in young patients with an Figure 1 Evolution of the PASP after PMV and during follow-up according to the presence (Group 1) or absence (Group 2) of severe PAH. echocardiographic score <8, large MVA before PMV, mild to moderate mitral regurgitation, male gender and absence of previous commissurotomy [19] . In the present study, both the Wilkins score >8 and the presence of AF were associated with a lower rate of periprocedural success. However, we did not find a significant relationship between the presence of PAH and success rate as has previously been described [20, 23] .
We observed a decrease of PASP to normal values after PMV that persisted over time. Both the immediate and long-term results were similar among patients with or without high PASP, consistent with other reports [22, 24] . Several studies evaluating patients treated with surgical valve replacement, have observed a significant decrease in PASP, achieving near normal levels [27, 28] . Braunwald et al. reported 31 surgical patients with PAH who underwent a postoperative decrease from 75 to 39 mmHg of PASP [6] . Zener et al., analysing 27 patients with MS and PASP >100 mmHg, also have observed a decrease from 115 to 50 mmHg after surgery [28] . Although the passive component of pulmonary hypertension decreased immediately after the procedure, the regression of pulmonary vascular resistance took more time [29] . The decline of PASP in our patients with PAH was significant at six months reaching normal values at one year, and remained stable until end of follow-up; however, some studies found a gradual increase in pulmonary pressure in patients who developed restenosis [28] .
We did not observe a significant relation between PAH before PMV and mortality during long-term follow-up.
The MVA showed a gradual decrease over time, which was similar in patients with and without PAH. Most registries showed a decrease of MVA in the five-year follow-up period between 0.12 to 0.20 cm 2 , related to an increase in the rate of restenosis. Several reports showed a wide variability in the incidence of restenosis (between 3% and 70%) from one to three years of follow-up [19] [20] [21] [22] 25, 30, 31] . The rate of Rs in our study was 29.4% at 60 months follow-up, and was not associated with the presence of PAH. This rate is similar to that reported by Hernández et al. who observed a rate of Rs of 39% after seven years of follow-up [31] . Fawzy reported that patients with a PASP >60 mmHg before PMV, had a slight increase in the rate of Rs and events during follow-up, compared with patients with PASP <60 mmHg; however, only an echocardiographic score > 8 and female gender resulted in independent predictors of Rs in this investigation [22] .
Study Limitations
The main limitation of this study is its retrospective nature, however, complete data were obtained in all patients, and 91% completed long-term follow-up. Pulmonary artery pressures were determined by echocardiography during follow-up and not by direct measurement due to the excellent concordance of echocardiography with the pressures recorded at the initial right heart catheterisation.
Conclusions
Based on the results observed, PMV is a safe and effective procedure in patients with severe PAH. The significant reduction in PASP after PMV was maintained at long-term follow-up with a significant improvement in NYHA functional class without differences between groups. Despite the gradual reduction in MVA, most patients remained asymptomatic at the end of follow-up.
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